KRAS is commonly mutated in NSCLC (~20%-30% in adenocarcinoma,[16]), with an estimated 70% of lung tumours displaying RAS-RAF-MAPK pathway activation [17]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.